Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX in Interstitial Cystitis/Bladder Pain Syndrome
NCT05141006Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2022
- Primary completion
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in interstitial cystitis (IC) comparing BOTOX with Placebo (2 arms). Primary endpoint: Change in Average Daily Worst Bladder Pain at 6 weeks. Started Mar 2022; status: completed.
02
Drugs
botulinum toxin
03
Conditions
interstitial cystitis (IC)
Beyond the preview
Go deeper on NCT05141006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05141006.